Teladoc (TDOC) Misses Q2 EPS by 11c, Revenues Beat

Teladoc (NYSE: TDOC) reported Q2 EPS of ($0.34), $0.11 worse than the analyst estimate of ($0.23). Revenue for the quarter came in at $241 million versus the consensus estimate of $220.67 million.

GUIDANCE:

Teladoc sees Q3 2020 EPS of ($0.35)-($0.30), versus the consensus of ($0.26). Teladoc sees Q3 2020 revenue of $275-285 million, versus the consensus of $216.87 million.

Teladoc sees FY2020 EPS of ($1.45)-($1.36), versus the consensus of ($1.13). Teladoc sees FY2020 revenue of $980-995 million, versus the consensus of $844.17 million.

Preliminary outlook for 2021:

Given the significant level of change in the marketplace, Teladoc Health is providing a preliminary outlook for expected revenue growth in 2021. For the full-year 2021, the company anticipates year-over-year revenue growth to be in the range of 30% to 40

For earnings history and earnings-related data on Teladoc (TDOC) click here.

You May Also Be Interested In

• Bristol-Myers Squibb (BMY) stock slips despite earnings beat
• CEMEX, S.A.B. de C.V. (CX) Tops Q1 EPS by 5c
• Esquire Financial Holdings, Inc. (ESQ) Tops Q1 EPS by 3c